Globus Medical, Inc.
GMED Healthcare Medical Devices
Globus Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 16.7% from fiscal 2024. In the quarter to June 2026, revenue grew 5.94%, EPS fell 25.3% and free cash flow grew 571.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for three.
Follow GMED
Globus Medical, Inc. (GMED) EV/Sales
As of 16 October 2026, Globus Medical, Inc. (GMED) trades at a EV/Sales of 3.4×. Over the past ten years it has ranged from 2.9× (July 2025) to 8.9× (June 2021); the current reading is higher than 7% of that period. That is above the Medical Devices industry median of 2.2× and in line with the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.1× | (7.29%) |
| FY2024 | 4.4× | 17.66% |
| FY2023 | 3.8× | (44.08%) |
| FY2022 | 6.8× | (5.30%) |
| FY2021 | 7.1× | (6.31%) |
| FY2020 | 7.6× | 8.16% |
| FY2019 | 7.0× | 28.80% |
| FY2018 | 5.5× | (8.07%) |
| FY2017 | 5.9× | 61.18% |
| FY2016 | 3.7× | (14.02%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.5× | (9.35%) |
| Mar 2026 | 3.8× | (6.90%) |
| Dec 2025 | 4.1× | 39.63% |
| Sep 2025 | 3.0× | (10.00%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | 1.5× |
| BRKR Bruker Corporation compare | 2.9× |
| ZBH Zimmer Biomet Holdings, Inc. compare | 3.0× |
| PODD Insulet Corporation compare | 3.3× |
| GMED Globus Medical, Inc. | 3.4× |
| BIO Bio-Rad Laboratories, Inc. compare | 3.5× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 3.6× |
| PEN Penumbra, Inc. compare | 8.0× |
| GKOS Glaukos Corporation compare | 15.9× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)